Raymond James raises Hinge Health price target to $80

0 min read | Published on 15 Jun 2026, 11:46 PM |Updated on 15 Jun 2026, 11:46 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

Raymond James analyst Brian Peterson maintained an Outperform rating on Hinge Health (NYSE: HNGE) and raised the price target to $80 from $70.

*this image is generated using AI for illustrative purposes only.

Raymond James analyst Brian Peterson has maintained an Outperform rating on Hinge Health (NYSE: HNGE) and raised the price target to $80, up from the previous target of $70. The adjustment reflects a revised outlook on the company's stock performance.

The rating affirmation and price target increase were issued by the analyst covering the stock. Hinge Health operates in the healthcare sector, and the new target suggests a positive trajectory for its shares.

Metric	Value
Rating	Outperform
Previous Price Target	$70
New Price Target	$80

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific factors drove Raymond James to revise Hinge Health's price target upward?

How might this rating boost impact Hinge Health's stock performance in the short term?

What are the potential growth catalysts for Hinge Health in the healthcare sector?

Canaccord Genuity raises Hinge Health price target to $76

0 min read | Published on 15 Jun 2026, 10:23 PM |Updated on 15 Jun 2026, 10:23 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Canaccord Genuity analyst Richard Close maintained a Buy rating on Hinge Health (NYSE: HNGE) and raised the price target to $76 from $65. The adjustment signals increased confidence in the digital health company's valuation potential.

*this image is generated using AI for illustrative purposes only.

Canaccord Genuity analyst Richard Close has maintained a Buy rating on Hinge Health (NYSE: HNGE) while raising the price target to $76 from $65. The adjustment reflects increased confidence in the company's valuation potential following recent market performance.

The revised target suggests an upside from current trading levels, reinforcing the analyst's positive stance on the digital health clinic's growth trajectory. Hinge Health operates in the musculoskeletal care sector, a market segment that has seen significant investor interest.

Rating and Price Action

The decision to upgrade the price target comes alongside a reaffirmation of the Buy recommendation. Key financial metrics associated with this rating update are detailed below.

Metric	Value
Rating	Buy
Previous Price Target	$65
New Price Target	$76

The new target of $76 represents a specific valuation benchmark set by Canaccord Genuity for the digital health provider. Investors will monitor Hinge Health's quarterly results to gauge progress toward this revised goal.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific growth drivers or market conditions does Canaccord Genuity expect will push Hinge Health's stock to the new $76 target?

How might increased investor interest in the musculoskeletal care sector impact Hinge Health's competitive positioning?

What upcoming quarterly results or milestones should investors watch to gauge progress toward the revised price target?